Intended for healthcare professionals


NICE approves monoclonal antibody dupilumab for severe asthma

BMJ 2021; 375 doi: (Published 18 October 2021) Cite this as: BMJ 2021;375:n2546
  1. Jacqui Wise
  1. Kent, UK

The National Institute for Health and Care Excellence has approved the monoclonal antibody dupilumab for patients with severe asthma who do not respond to conventional treatments.1 Asthma charities say the drug could be a game changer but only if patients are able to access it.

Dupilumab is a recombinant human monoclonal antibody that inhibits interleukin-4 and interleukin-13 signalling, thus reducing inflammation. In clinical trials it has been shown to reduce the frequency of asthma attacks and the use of emergency steroid tablets by almost half when combined with standard inhaler …

View Full Text

Log in

Log in through your institution


* For online subscription